Company intelligence / Profile preview
IDBiologics
Nashville, Tennessee, United Statesidbiologics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has 6 clinical lead candidate molecules with robust animal proof of concept. Currently developing a two-antibody medicine against Rift Valley fever virus through preclinical development and Phase 1 clinical studies.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
United States Department of DefenseVanderbilt University Medical CenterGlobal Pandemic Prevention and Biodefense Center
Beyond the preview
Go deeper on IDBiologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDBiologics.